Burkard, Theresa; Vallejo-Yagüe, Enriqueta; Lauper, Kim; Finckh, Axel; Hügle, Thomas; Burden, Andrea M (2023). Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab. RMD open, 9(4), e003396. BMJ Publishing Group 10.1136/rmdopen-2023-003396
|
Text
e003396.full.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (784kB) | Preview |
OBJECTIVES
Treatment response is worse in obese patients with rheumatoid arthritis (RA), including patients on weight-adjusted therapies like infliximab. We aimed to assess the association between body mass index (BMI) and changes in RA disease activity and radiographic progression over time.
METHODS
We included infliximab users with an RA diagnosis in the Swiss Clinical Quality Management in Rheumatic Diseases registry (1997-2020). Two cohorts were defined: (1) starting from their first BMI measurement or disease activity score (DAS28-esr), and (2) from their first BMI measurement or radiographic assessment (Rau score). We evaluated the coefficient and 95% CI of BMI with changes in mean DAS28-esr (cohort 1) and mean Rau scores (a structural joint damage score, cohort 2) using generalised estimation equations, overall and stratified by BMI categories.
RESULTS
Cohort 1 comprised 412 patients (74% women, mean age 53 years, mean BMI 25). We observed no change in mean DAS28-esr with increasing BMI overall (adjusted coefficient: 0.00, 95% CI -0.02 to 0.02), or in BMI categories. Cohort 2 comprised 187 patients highly alike to those in cohort 1. We observed a significant decrease of 1.05 in mean Rau scores for every increase in BMI unit (adjusted coefficient: -1.05, 95% CI -1.92 to -0.19). Results remained statistically non-significant across BMI categories.
CONCLUSIONS
Our longitudinal investigation suggests that BMI increase may not lead to changes in DAS28-esr in patients receiving infliximab, despite the weight-adapted dose. Yet, there may be a decrease in erosions with increasing weight non-limited to obese patients.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM) |
UniBE Contributor: |
Vallejo Yagüe, Enriqueta |
Subjects: |
600 Technology > 610 Medicine & health 300 Social sciences, sociology & anthropology > 360 Social problems & social services |
ISSN: |
2056-5933 |
Publisher: |
BMJ Publishing Group |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
09 Oct 2023 10:14 |
Last Modified: |
12 Oct 2023 15:53 |
Publisher DOI: |
10.1136/rmdopen-2023-003396 |
PubMed ID: |
37802600 |
Uncontrolled Keywords: |
Disease Activity infliximab rheumatoid arthritis |
BORIS DOI: |
10.48350/186965 |
URI: |
https://boris.unibe.ch/id/eprint/186965 |
Actions (login required)
 |
Edit item |